Search results
Mission Wealth Management LP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 3 days agoMission Wealth Management LP bought a new position in Moderna, Inc. (NASDAQ:MRNA – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities ...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 5 days agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 5 days ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 4 days agoModerna experienced a substantial financial shift in the first quarter (Q1) of 2024, reporting a net loss of $1.2bn - a stark contrast to its net income...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 5 days agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna (MRNA) Set to Announce Earnings on Thursday
ETF DAILY NEWS· 6 days agoModerna (NASDAQ:MRNA – Get Free Report) will be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Moderna to post ...
How mRNA vaccines could be personalized cancer cures
Axios· 6 hours agoWhy it matters: This personalized approach could make conditions like melanoma and bladder, kidney, pancreatic and breast cancers treatable, and even...
Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight
FierceBiotech· 6 days agoEarlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks. Back in 2021 ...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 5 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company’s first quarter ...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 5 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...